Ravindra Majeti, Ph.D.
Affiliations: | University of California, San Francisco, San Francisco, CA |
Area:
Signal transduction in lymphocytesGoogle:
"Ravindra Majeti"Mean distance: 10.8 | S | N | B | C | P |
Parents
Sign in to add mentor| Arthur Weiss | grad student | 2000 | UCSF | |
| (Negative regulation of the receptor protein tyrosine phosphatase CD45 by dimerization is mediated by an inhibitory structural wedge.) | ||||
| Irving L. Weissman | post-doc | 2005-2009 | Stanford University Medical School (FlyTree) | |
Children
Sign in to add trainee| Adriel Cha | research assistant | 2008-2010 | (Stem Cell Tree) |
| Amy C Fan | grad student | 2017- | Stanford (Stem Cell Tree) |
| Mark Chao | grad student | 2008-2010 | |
| Max Jan | grad student | 2008-2011 | |
| Ryan Corces | grad student | 2010-2015 | Stanford Medical School |
| Steven Chan | post-doc | University of Toronto | |
| Brian Jonas | post-doc | UC Davis | |
| Andreas Reinisch | post-doc | 2012-2017 | University of Graz |
| Daniel Thomas | post-doc | 2012-2019 | University of Adelaide, Australia |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Landberg N, Köhnke T, Feng Y, et al. (2023) IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation. Blood Cancer Discovery |
| Nelde A, Schuster H, Heitmann JS, et al. (2023) Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discovery. OF1-OF22 |
| Sayitoglu EC, Luca BA, Boss AP, et al. (2023) AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML. Biorxiv : the Preprint Server For Biology |
| Fan AC, Nakauchi Y, Bai L, et al. (2023) RUNX1 loss renders hematopoietic and leukemic cells dependent on interleukin-3 and sensitive to JAK inhibition. The Journal of Clinical Investigation |
| Kotini AG, Carcamo S, Cruz-Rodriguez N, et al. (2023) Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia. Blood Cancer Discovery. OF1-OF18 |
| Sconocchia T, Foßelteder J, Köhnke T, et al. (2023) Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells. Journal of Visualized Experiments : Jove |
| Linde MH, Fan AC, Kohnke T, et al. (2023) Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy. Cancer Discovery |
| Thomas D, Wu M, Nakauchi Y, et al. (2022) Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery |
| Chen J, Johnson L, McKenna K, et al. (2022) MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS). Clinical Lymphoma, Myeloma & Leukemia. S317-S318 |
| Bassal MA, Samaraweera SE, Lim K, et al. (2022) Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications. 13: 4131 |